172 related articles for article (PubMed ID: 11432356)
1. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
[TBL] [Abstract][Full Text] [Related]
2. Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.
Takahashi N; Suzuki H; Iwabuchi S; Yamazaki Y; Yanaga K
Hepatogastroenterology; 2005; 52(61):326-8. PubMed ID: 15783061
[TBL] [Abstract][Full Text] [Related]
3. [A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].
Iwasaki K; Komuro Y; Masumoto N; Asaoka K; Ishitani K
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1483-6. PubMed ID: 10500539
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
[TBL] [Abstract][Full Text] [Related]
5. [New regimens for the treatment of gynecologic cancers].
Sugiyama T; Ushijima K; Kamura T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
[TBL] [Abstract][Full Text] [Related]
6. [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Kawashima T; Murakami H; Kanamori T; Nakamura Y
Gan To Kagaku Ryoho; 2007 Mar; 34(3):461-3. PubMed ID: 17353644
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
[TBL] [Abstract][Full Text] [Related]
8. [Promising new drugs for gynecological cancer].
Yakushiji M; Sugiyama T; Ushijima K
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1932-7. PubMed ID: 9350238
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
10. [Second-line chemotherapy for recurrent ovarian cancer].
Sugiyama T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):28-32. PubMed ID: 15675578
[TBL] [Abstract][Full Text] [Related]
11. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
12. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
14. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Terauchi F
Nihon Rinsho; 2004 Oct; 62 Suppl 10():175-8. PubMed ID: 15535228
[No Abstract] [Full Text] [Related]
15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
17. [Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)].
Yasuda M; Kimura E; Ochiai K; Tada S; Udagawa Y; Aoki D; Nozawa S; Kikuchi Y; Kita T; Nishida M; Tsunoda H
Gan To Kagaku Ryoho; 2001 Apr; 28(4):493-8. PubMed ID: 11329783
[TBL] [Abstract][Full Text] [Related]
18. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
Misawa A; Yasuda M
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
20. [A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].
Kitagawa D; Nako Y; Honda Y; Shigekawa T; Horiguchi K; Aruga T; Yamashita T; Kuroi K
Gan To Kagaku Ryoho; 2012 Jun; 39(6):1013-6. PubMed ID: 22705705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]